Responses
Cardiovascular medicine
Protocol
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 15 March 2016
- Published on: 15 March 2016The choice of drugs should be contemporary and well-provenShow More
I read with interest the protocol. The idea of comparing initial monotherapy vs dual-drug therapy is timely.
However, the choice of antihypertensive drugs could have been better. Losartan is an angiotensin receptor blocker (ARB). Recently the use of ARB as an antihypertensive drug is seriously questioned. Despite lowering blood pressure, it is not shown to improve cardiovascular outcomes (heart attack, stroke and...
Conflict of Interest:
None declared.